KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Deferred Taxes: 2021-2024

Historic Deferred Taxes for Halozyme Therapeutics (HALO) over the last 4 years, with Dec 2024 value amounting to -$532,000.

  • Halozyme Therapeutics' Deferred Taxes fell 9267.81% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 91.64%. This contributed to the annual value of -$532,000 for FY2024, which is 98.46% up from last year.
  • According to the latest figures from FY2024, Halozyme Therapeutics' Deferred Taxes is -$532,000, which was up 98.46% from -$34.5 million recorded in FY2023.
  • Halozyme Therapeutics' 5-year Deferred Taxes high stood at $155.4 million for FY2021, and its period low was -$40.0 million during FY2022.
  • Its 3-year average for Deferred Taxes is -$25.0 million, with a median of -$34.5 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Deferred Taxes slumped by 125.74% in 2022 and then skyrocketed by 98.46% in 2024.
  • Yearly analysis of 4 years shows Halozyme Therapeutics' Deferred Taxes stood at $155.4 million in 2021, then slumped by 125.74% to -$40.0 million in 2022, then rose by 13.75% to -$34.5 million in 2023, then surged by 98.46% to -$532,000 in 2024.